T-cell therapy for rheumatologic disease is now expanding out of academe into the commercial space, with encouraging new data ...

Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which ...

T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

Marcela Maus , MD, PhD, director of the Cellular Immunotherapy Program and the Paula J. O'Keeffe Endowed Chair of the Mass ...

To assess T-cell-induced morphological changes, each organoid was segmented in the transmitted light (TL) channel using a ...

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell lymphoma, ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous ...

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...

T-cell therapy has shown remarkable clinical efficacy in haematological malignancies, currently representing a well ...